Arecor receives £2.8m grant for rapid insulin product
pharmafile | March 31, 2021 | News story | Research and Development | diabetes, insulin
Arecor has announced today that it has received a £2.8 million grant from Innovate UK, to support the Phase II development of AT247, its ultra-rapid acting insulin product candidate which is aimed to help those with Type 1 diabetes.
AT247 is a novel proprietary formulation of insulin and has been designed to accelerate insulin absorption, post injection, to achieve more effective and controlled management of blood glucose levels.
The grant will support the development programme, which will include a Phase II clinical trial to compare the glycaemic control, safety and tolerability of AT247 with Fiasp when administered by insulin pump over an extended period.
Continuous glucose monitoring will allow the assessment of time spent with blood glucose level in a healthy range, the control of which is crucial for avoiding episodes of hyper- and hypo-glycaemia and delivering positive long-term health outcomes for people with Type 1 diabetes.
Sarah Howell, Chief Executive Officer of Arecor, said: “We are proud that Innovate UK has, through their thorough technical and commercial review process, chosen to invest in our research from across the very best of British science. Diabetes remains a significant and growing health problem throughout the world.
“AT247, the lead product from our pipeline of next generation rapid insulins is focused on transforming the lives of people living with Type 1 diabetes through its potential to enable greater glucose control. This control is critical in helping patients to avoid hyper- and hypo-glycaemia events, improve time in range and reduce overall disease complications.”
Despite significant advances in treatment options, 79% of people with diabetes live with severe complications due to time spent outside of their target blood glucose range. It has been shown that blood glucose control and time in range can be improved when patients are using an automated insulin delivery system, where blood glucose is continuously measured, whilst an algorithm calculates insulin requirements based on real-time blood glucose which is then automatically delivered by a pump. AT247 has the potential to be an ideal pump insulin thereby enabling a closed loop artificial pancreas for patients with Type I diabetes.
Dr Thomas Pieber, PI for the Phase II study at Medical University of Graz, said: “AT247 is a very promising candidate in the pursuit for next generation insulins designed to improve postprandial glycaemic control and flexibility of insulin dosing.
“The Phase II development programme will build on the early clinical evidence that AT247 has highly favourable pharmacokinetic properties and may facilitate a fully closed loop artificial pancreas, a potentially life changing treatment option for people living with diabetes.”
The Phase II trial is expected to commence in early 2022.
Kat Jenkins
Related Content
MetP Pharma releases positive data on intranasal semaglutide administration
MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering …
AOTI diabetic foot care therapy to be used by NHS
Effective from September 2025, AOTI’s Topical Wound Oxygen (TWO2) therapy has been awarded inclusion in …
Recce Pharmaceuticals reports positive phase 2 data for skin infection drug
Recce Pharmaceuticals have announced positive patient data from its phase 2 clinical trial into RECCE …
